Disparity Emerges in Lilly Data on Schizophrenia Drug
December 22nd, 2006By ALEX BERENSON
For at least a year, Eli Lilly provided information to doctors about the blood-sugar risks of its drug Zyprexa that did not match data that the company circulated internally when it first reviewed its clinical trial results, according to company documents.